Somatostatin Receptor Type 2 Market 2020: Global Trend, Growth Opportunities and Forecast 2025
Added: (Thu Sep 10 2020)
Pressbox (Press Release) -
Global Somatostatin Receptor Type 2 Market 2020-2025 examines the market in detail along with focusing on significant market dynamics for the key players in the market. This research report offers granulated yet in-depth analysis of revenue share, market segments, revenue estimates and various regions across the globe.
Somatostatin receptor type 2 is a protein that in humans is encoded by the SSTR2 gene. The SSTR2 gene is located on chromosome 17 on the long arm in position 25.1 in humans. It is also found in most other vertebrates. In the pancreas, after binding to somatostatin, it inhibits the secretion of pancreatic enzymes. During development, it stimulates neuronal migration and axon outgrowth The Global Somatostatin Receptor Type 2 Market is segmented on the basis of Product Type, Application, End Use Industry and Region. This report also covers all the regions and countries of the world, which shows a regional development status, including market size.
Available Exclusive Sample Copy of this Report @ https://www.businessindustryreports.com/sample-request/61703 .
On the Basis of Product Type segment, the Somatostatin Receptor Type 2 Market is sub segmented into CRN-00808, Lanreotide Acetate, PRL-2903 and Others. Based on End Use Industry segment, the Somatostatin Receptor Type 2 Market is segmented as Hormonal Disorder, Oncology, Metabolic Disorder and Others. Somatostatin receptor 2 also has the ability to stimulate apoptosis in many cells including cancer cells. The somatostatin receptor 2 is also being looked at as a possible target in cancer treatment for its ability to inhibit tumor growth.
There are several manufacturers of Somatostatin Receptor Type 2 in Europe and North America. In North America, the demand for Somatostatin Receptor Type 2 is primarily driven by the Healthcare sector. Among the countries in Asia Pacific, the demand was substantially high in developing countries such as China and India.
Purchase this report online with 90 Pages, List of Tables & Figures and in-depth Table of Contents on “Somatostatin Receptor Type 2 Market Report 2020” @ https://www.businessindustryreports.com/buy-now/61703/single .
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study.
Top Industry News:
Ipsen joins clinical collaboration to evaluate cabozantinib (CABOMETYX) plus atezolizumab in metastatic non-small cell lung cancer and metastatic castration-resistant prostate cancer on 02 July, 2020 -- Ipsen, today announced it will join the Exelixis and Roche clinical collaboration and participate in the funding of the recently initiated CONTACT-01 and CONTACT-02 global Phase III pivotal trials. CONTACT-01 is evaluating the safety and efficacy of cabozantinib (CABOMETYX) in combination with atezolizumab (TECENTRIQ) in patients with metastatic non-small cell lung cancer (NSCLC) who have been previously treated with an immune checkpoint inhibitor and platinum-containing chemotherapy. CONTACT-02 is evaluating the safety and efficacy of cabozantinib given in combination with atezolizumab versus a second novel hormonal therapy (NHT) in men with metastatic castration-resistant prostate cancer (CRPC) who have previously been treated with one NHT.
“There is a growing body of preclinical and clinical evidence that cabozantinib may positively impact treatment when paired with immunotherapy,” said Dr. Howard Mayer, Executive Vice President and Head of Research and Development at Ipsen. “We are pleased to enter into this collaboration with Exelixis and Roche to build on the promising data from COSMIC-021 and further examine the potential of cabozantinib in combination with atezolizumab to treat metastatic non-small cell lung cancer and for men with metastatic castration-resistant prostate cancer.”
“Ipsen has built its strength in oncology through solid long-term partnerships which are evaluating new approaches to target difficult-to-treat cancers. This marks an important milestone in our partnership with Exelixis to further develop cabozantinib and our shared vision to progress the treatment for cancers and indications with high unmet need, ensuring no patient is left behind,” said Bartek Bednarz, Senior Vice President, Global Product & Portfolio Strategy at Ipsen.
Grab Your Report at an Impressive Discount @ https://www.businessindustryreports.com/check-discount/61703 .
Major Key Players:
Some of the Somatostatin Receptor Type 2 Market manufacturers involved in the market are Amryt Pharma plc, Crinetics Pharmaceuticals Inc, Daewoong Pharmaceutical Co Ltd, Ipsen SA, Progenics Pharmaceuticals Inc, Strongbridge Biopharma plc, Zucara Therapeutics Inc in World, effective mergers are some of the strategies adopted by the Somatostatin Receptor Type 2 Market manufacturers. New product launches and continuous technological innovations are the Somatostatin Receptor Type 2 Market strategies adopted by the major players.
Table of Contents:
About us
BusinessindustryReports.com is digital database of comprehensive market reports for global industries. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined – we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.
Media Contact
Business Industry Reports
Pune – India
sales@businessindustryreports.com
+19376349940